$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2018 Q1 Form 10-Q Financial Statement

#000156459018011031 Filed on May 04, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $2.900M $18.96M
YoY Change -84.7% 159.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $72.45M $38.50M
YoY Change 88.17% 82.46%
% of Gross Profit
Research & Development $96.86M $86.98M
YoY Change 11.35% -9.65%
% of Gross Profit
Depreciation & Amortization $3.200M $3.000M
YoY Change 6.67% -34.8%
% of Gross Profit
Operating Expenses $169.3M $125.5M
YoY Change 34.93% 6.9%
Operating Profit -$147.4M -$106.5M
YoY Change 38.39% -3.2%
Interest Expense $5.800M $2.100M
YoY Change 176.19% 16.67%
% of Operating Profit
Other Income/Expense, Net $6.129M -$779.0K
YoY Change -886.78% -111.04%
Pretax Income -$141.3M -$107.3M
YoY Change 31.68% 4.19%
Income Tax -$62.00K
% Of Pretax Income
Net Earnings -$141.2M -$107.3M
YoY Change 31.62% 4.19%
Net Earnings / Revenue -4869.45% -565.88%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.412M -$1.248M
COMMON SHARES
Basic Shares Outstanding 99.87M 86.01M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.568B $556.9M
YoY Change 181.53% -43.15%
Cash & Equivalents $396.1M $171.1M
Short-Term Investments $1.172B $385.8M
Other Short-Term Assets $66.70M $18.10M
YoY Change 268.51% -34.42%
Inventory
Prepaid Expenses
Receivables $50.80M $19.50M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.685B $597.2M
YoY Change 182.21% -43.13%
LONG-TERM ASSETS
Property, Plant & Equipment $202.0M $130.0M
YoY Change 55.43% 253.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $600.0K $255.3M
YoY Change -99.76% 11.68%
Other Assets $35.20M $1.471M
YoY Change 2292.93% 0.0%
Total Long-Term Assets $237.8M $536.7M
YoY Change -55.69% 101.12%
TOTAL ASSETS
Total Short-Term Assets $1.685B $597.2M
Total Long-Term Assets $237.8M $536.7M
Total Assets $1.923B $1.134B
YoY Change 69.6% -13.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.20M $25.37M
YoY Change -47.97% 45.46%
Accrued Expenses $63.80M $31.84M
YoY Change 100.36% 3.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $115.4M $95.79M
YoY Change 20.48% 44.32%
LONG-TERM LIABILITIES
Long-Term Debt $30.00M $150.0M
YoY Change -80.0%
Other Long-Term Liabilities $23.00M $3.184M
YoY Change 622.36% 131.9%
Total Long-Term Liabilities $53.00M $3.184M
YoY Change 1564.57% 131.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $115.4M $95.79M
Total Long-Term Liabilities $53.00M $3.184M
Total Liabilities $168.3M $303.0M
YoY Change -44.46% 136.93%
SHAREHOLDERS EQUITY
Retained Earnings -$2.079B -$1.764B
YoY Change 17.88% 30.71%
Common Stock $2.629B
YoY Change 3.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.755B $830.9M
YoY Change
Total Liabilities & Shareholders Equity $1.923B $1.134B
YoY Change 69.6% -13.9%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$141.2M -$107.3M
YoY Change 31.62% 4.19%
Depreciation, Depletion And Amortization $3.200M $3.000M
YoY Change 6.67% -34.8%
Cash From Operating Activities -$155.7M -$100.3M
YoY Change 55.2% 19.98%
INVESTING ACTIVITIES
Capital Expenditures $21.26M $36.15M
YoY Change -41.2% 1210.33%
Acquisitions
YoY Change
Other Investing Activities -$113.6M $111.2M
YoY Change -202.16% -14.33%
Cash From Investing Activities -$134.8M $75.10M
YoY Change -279.51% -36.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.52M 2.700M
YoY Change 1437.85% -83.23%
NET CHANGE
Cash From Operating Activities -155.7M -100.3M
Cash From Investing Activities -134.8M 75.10M
Cash From Financing Activities 41.52M 2.700M
Net Change In Cash -249.0M -22.50M
YoY Change 1006.47% -144.64%
FREE CASH FLOW
Cash From Operating Activities -$155.7M -$100.3M
Capital Expenditures $21.26M $36.15M
Free Cash Flow -$176.9M -$136.5M
YoY Change 29.66% 58.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86984000
CY2018Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
50768000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
66665000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
1685297000
CY2018Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
648000
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
35855000
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7676000
CY2018Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
21899000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96857000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72447000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38487000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
169304000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
125471000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-147405000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-106511000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
5794000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2128000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
335000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2907000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6129000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-779000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141276000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107290000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-62000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-107290000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
42094000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86027000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1936000
CY2017Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
608000
CY2018Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
16766000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27540000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9042000
CY2018Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-11767000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
26961000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-155664000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21257000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
358433000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
244876000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-134814000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
75076000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2769000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
572000
CY2017Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
53000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
41522000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2716000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-248956000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22538000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
646832000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
195088000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
397876000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
172550000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1727000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1471000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2079475000
CY2018Q1 us-gaap Deferred Revenue
DeferredRevenue
16570000
CY2018Q1 us-gaap Deferred Revenue
DeferredRevenue
43531000
CY2018Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5883000
CY2018Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1174424000
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2066000
CY2018Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1172363000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1060817000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1653000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1059176000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1173776000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
648000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12672000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12211000
CY2018Q1 us-gaap Stockholders Equity Period Increase Decrease
StockholdersEquityPeriodIncreaseDecrease
-11600000
CY2018Q1 alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D
CY2018Q1 alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
CY2018Q1 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7242000
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9328000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1171715000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
648000
CY2018Q1 alny Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
-800000

Files In Submission

Name View Source Status
0001564590-18-011031-index-headers.html Edgar Link pending
0001564590-18-011031-index.html Edgar Link pending
0001564590-18-011031.txt Edgar Link pending
0001564590-18-011031-xbrl.zip Edgar Link pending
alny-10q_20180331.htm Edgar Link pending
alny-20180331.xml Edgar Link completed
alny-20180331.xsd Edgar Link pending
alny-20180331_cal.xml Edgar Link unprocessable
alny-20180331_def.xml Edgar Link unprocessable
alny-20180331_lab.xml Edgar Link unprocessable
alny-20180331_pre.xml Edgar Link unprocessable
alny-ex101_216.htm Edgar Link pending
alny-ex102_217.htm Edgar Link pending
alny-ex103_215.htm Edgar Link pending
alny-ex104_214.htm Edgar Link pending
alny-ex311_6.htm Edgar Link pending
alny-ex312_9.htm Edgar Link pending
alny-ex31_218.htm Edgar Link pending
alny-ex321_8.htm Edgar Link pending
alny-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805041909133091173.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending